16 December 2025
Oryzon’s 10th anniversary. CEO Carlos Buesa highlights that listing reinforces transparency and good governance, which are key to investor confidence and stable growth.
Oryzon develops experimental drugs in a highly regulated sector requiring long timeframes and sustained investment; therefore, listing on regulated markets was a strategic decision given the difficulty of accessing private financing in Spain.
Oryzon Genomics S.A. (ORY.MC) yahoo finance
Links
